Skip to main content
SpringerLink
Log in
Book cover

Chirurgie oncoplastique et reconstruction dans le cancer du sein pp 145–148Cite as

Mammectomie prophylactique et mutations des gènes BRCA1 ou BRCA2

  • Chapter

  • 397 Accesses

Abstrait

Lorsque, dans une famille, il existe plusieurs personnes atteintes de cancers du sein ou de l’ovaire, on peut suspecter une prédisposition génétique (PG) à ces cancers. Face à un contexte familial évocateur (tableau I), une consultation d’oncogénétique doit être proposée. Elle peut permettre d’aboutir à la mise en évidence d’une mutation constitutionnelle des gènes BRCA1 ou BRCA2 dans la famille.

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Antoniou A, Pharoah PD, Narod S, et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5): 1117–30

    Article  PubMed  CAS  Google Scholar 

  2. Hartmann LC, Schaid DJ, Woods JE, et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340(2): 77–84

    Article  PubMed  CAS  Google Scholar 

  3. Hartmann LC, Sellers TA, Schaid DJ, et al. (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93(21): 1633–7

    PubMed  CAS  Google Scholar 

  4. Meijers-Heijboer H, van Geel B, van Putten WL, et al. (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345(3): 159–64

    Article  PubMed  CAS  Google Scholar 

  5. Rebbeck T, Friebel T, Lynch H, et al. (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutations carriers: the PROSE study group. J Clin Oncol 22(6): 1055–62

    Article  PubMed  Google Scholar 

  6. Bermejo-Pérez M, Marquez-Calderon S, Llanos-Méndes A (2007) Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121: 225–31

    Article  PubMed  CAS  Google Scholar 

  7. Stefanek M, Helzlsouer KJ, Wilcox P, et al. (1995) Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med 24: 412–9

    Article  PubMed  CAS  Google Scholar 

  8. Borgen PI, Hill AD, Tran KN, et al. (1998) Patient regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 5(7): 603–6

    Article  PubMed  CAS  Google Scholar 

  9. Frost MH, Schaid DJ, Sellers TA, et al. (2000) Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284(3): 319–24

    Article  PubMed  CAS  Google Scholar 

  10. Hatcher MB, Fallowfield L, A’Hern R (2001) The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. BMJ 322(7278): 76

    Article  PubMed  CAS  Google Scholar 

  11. vanOostrom I, MeijersHeijboer H, Lodder L, et al. (2003) Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5 year follow-up study. J Clin Oncol 21: 3867–74

    Article  Google Scholar 

  12. Metcalfe K, Esplen M, Goel V, et al. (2004) Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. Psychooncology 13: 14–25

    Article  PubMed  Google Scholar 

  13. Bresser P, Seynaeve C, Vangool A, et al. (2006) Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg 117: 1675–82

    Article  PubMed  CAS  Google Scholar 

  14. Saslow D, Boetes C, Burke W, et al. (2007) American Cancer Society Guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57: 75–89

    Article  PubMed  Google Scholar 

  15. Kriege M, Brekelmans C, Boetes C, et al. (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5): 427–37

    Article  PubMed  CAS  Google Scholar 

  16. Kuhl C, Schrading S, Leutner C, et al. (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk of breast cancer. J Clin Oncol 23(33): 8469–76

    Article  PubMed  Google Scholar 

  17. MARIBS. MARIBS Study group (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365: 1769–78

    Article  Google Scholar 

  18. Lehman C, Blume J, Weatherall P, et al. (2005) Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 103: 1898–905

    Article  PubMed  Google Scholar 

  19. Warner E, Plewes D, Hill K, et al. (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292: 1317–25.

    Article  PubMed  CAS  Google Scholar 

  20. Rebbeck T, Lynch H, Neuhausen S (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616–22

    Article  PubMed  Google Scholar 

  21. Pujol P, This P, Noruzinia M, et al. (2004) Estrogens, antiestrogens and familial breast cancer. Bull Cancer 91(7–8): 583–91

    PubMed  CAS  Google Scholar 

  22. Fisher B, Costantino J, Wickerham D, et al. (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P1-Study. J Natl Cancer Inst 97: 1652–62

    Article  PubMed  CAS  Google Scholar 

  23. Cuzick J, Forbes J, Sestak I, et al. (2007) Long-term results of tamoxifen prophylaxis for breast cancer-96 Month Follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99: 272–82

    Article  PubMed  CAS  Google Scholar 

  24. Powles T, Ashley S, Tidy A, et al. (2007) Twenty-year follow-up of the Royal Marsden Randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99: 283–90

    Article  PubMed  CAS  Google Scholar 

  25. Cuzick J, Powles T, Veronesi U, et al. (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354): 296–300

    Article  PubMed  CAS  Google Scholar 

  26. Vogel V, Costantino J, Wickerham D, et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifen (STAR) P2 trial. JAMA 295: 2727–41

    Article  PubMed  CAS  Google Scholar 

  27. Eisinger F, Alby N, Bremond A, et al. (1998) [INSERMFNCLCC collective expert’s report. Recommendations for management of women having a genetic risk of developing breast and/or ovarian cancer. National Federation of Centers of the Fight Against Cancer]. Ann Endocrinol 59(6): 470–84

    CAS  Google Scholar 

  28. Eisinger F, Bressac B, Castaigne D, et al. (2004) Identification et prise en charge des prédispositions héréditaires aux cancers du sein et de l’ovaire (mise à jour 2004). Bull Cancer 91(3): 219–37

    PubMed  Google Scholar 

  29. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al. (2000) Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 18(24):4053–9

    PubMed  CAS  Google Scholar 

  30. Bonadona V, Dussart-Moser S, Voirin N, et al. (2007) Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat 101(2): 233–45

    Article  PubMed  CAS  Google Scholar 

  31. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al. (2007) Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1-and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43(5): 867–76

    Article  PubMed  CAS  Google Scholar 

  32. Metcalfe K, Lynch HT, Ghadirian P, Tung N, et al. (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22(12): 2328–35

    Article  PubMed  CAS  Google Scholar 

  33. Vansprundel T, Schmidt M, Rookus M, et al. (2005) Risk reduction of controlateral breast cancer and survival after controlateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93: 287–92

    Article  CAS  Google Scholar 

  34. Kirova YM, Stoppa-Lyonnet D, Savignoni A, et al. (2005). Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 41(15): 2304–11

    Article  PubMed  Google Scholar 

  35. Pierce LJ, Levin AM, Rebbeck TR, et al. (2006) Ten-year multiinstitutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24(16): 2437–43

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag France, Paris

About this chapter

Cite this chapter

(2008). Mammectomie prophylactique et mutations des gènes BRCA1 ou BRCA2. In: Chirurgie oncoplastique et reconstruction dans le cancer du sein. Springer, Paris. https://doi.org/10.1007/978-2-287-71476-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-71476-4_12

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-71475-7

  • Online ISBN: 978-2-287-71476-4

Publish with us

Policies and ethics

Search

Navigation